DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

The stock's fall snapped a two-day winning streak.

Explore DexCom stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DXCM. FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $26.2 billion by ...